UK Portfolio Weekly Review — 15 June 2026
The UK Portfolio remains a compact, high-conviction regional portfolio with two open positions: Oxford Instruments plc and QinetiQ Group plc. Both positions are identified in the portfolio as London Stock Exchange holdings, which keeps the portfolio aligned with its country mandate. However, the stored symbols, OXINF and QNTQF, resemble U.S. OTC identifiers rather than the primary London tickers, so the key operational watch item is to confirm that the portfolio is tracking and, where possible, executing against the most liquid LSE lines rather than less liquid secondary quotes.
Current Positioning
- Oxford Instruments plc (OXINF): specialist scientific instrumentation and advanced technology exposure. Picked 2026-06-06. Stored performance: -14.25%.
- QinetiQ Group plc (QNTQF): UK defence technology, testing, training, engineering and mission-support exposure. Picked 2026-06-10. Stored performance: 0.00%.
This is not yet a diversified UK market portfolio. It is concentrated in two mid-cap industrial technology names, with a clear tilt toward science, defence, engineering, government spending and advanced manufacturing. That focus is acceptable for a young portfolio, but future additions should broaden exposure across the UK opportunity set rather than simply adding another defence or instrumentation name.
Recent Performance Drivers
Oxford Instruments is the performance drag this week. The stored quote history shows the position down 14.25% from the first quote to the latest quote. That decline should be monitored, but it is not by itself a sell signal. The company’s FY26 preliminary results were mixed: order intake rose to £450.4 million, while revenue fell to £423.2 million and adjusted operating profit declined to £73.7 million. Oxford also completed the disposal of its NanoScience business, which simplifies the group but may leave investors reassessing the growth profile after the restructuring. ([investegate.co.uk](https://www.investegate.co.uk/announcement/rns/oxford-instruments–oxig/preliminary-results/9607756))
The more constructive side of the Oxford case is that Advanced Technologies order intake rose sharply, and management indicated that planned FY27 revenue is now largely covered. That helps support a patient stance while the market digests the post-disposal shape of the business. ([investegate.co.uk](https://www.investegate.co.uk/announcement/rns/oxford-instruments–oxig/preliminary-results/9607756))
QinetiQ provides a steadier counterweight. The company reported FY26 record order intake of £3.573 billion and a record year-end backlog of £4.8 billion. Underlying operating profit rose 18% to £218 million, the underlying operating margin improved to 11.3%, and free cash flow rose 41% to £159 million. Management also increased the full-year dividend by 24% and announced a £200 million extension to the buyback programme. ([investegate.co.uk](https://www.investegate.co.uk/announcement/rns/qinetiq-group–qq./qinetiq-full-year-results-2026/9578814))
Portfolio Risk and Concentration
The main risk is concentration. With only two holdings, single-stock volatility can dominate the weekly result. Oxford’s early drawdown is already large enough to affect portfolio optics, while QinetiQ’s exposure to defence budgets, UK government programmes, execution risk and international contract timing means it is not a low-risk defensive holding despite its strong backlog.
The second risk is factor overlap. Although the companies operate in different end markets, both are UK-listed industrial technology businesses. The portfolio has little direct exposure to UK banks, energy, consumer staples, healthcare, infrastructure, utilities or large-cap exporters. For a country portfolio, that means the current holdings are thematically interesting but not yet representative of the broader UK equity market.
The third risk is liquidity and quote mapping. The portfolio should keep its main-exchange discipline by prioritising LSE liquidity. If the system is using OXINF and QNTQF only as stored quote symbols while the intended exchange is London, this is acceptable as a data-mapping issue. If the actual investable lines are OTC rather than LSE, that would need review because wider spreads and lower liquidity can impair execution quality.
Decision: No Closures This Week
No open position should be closed in this review. Both holdings are new and protected by the minimum holding-period rule. More importantly, neither has presented a clear portfolio-management reason to exit. Oxford’s price action is negative, but the thesis has not broken; the issue is whether order growth and the streamlined portfolio can translate into better FY27 revenue and margin momentum. QinetiQ’s fundamentals remain supportive, with backlog visibility, cash generation and shareholder returns all strengthening in the latest results.
What to Watch Next
- Oxford Instruments: evidence that stronger orders convert into revenue growth, especially in Advanced Technologies; margin recovery after restructuring; market reaction to the NanoScience disposal; and any update on FY27 visibility.
- QinetiQ: conversion of the £4.8 billion backlog into revenue, delivery on FY27 guidance for 3% to 5% revenue growth and 11.0% to 11.5% operating margin, progress in the U.S. business review, and continued buyback execution. ([investegate.co.uk](https://www.investegate.co.uk/announcement/rns/qinetiq-group–qq./qinetiq-full-year-results-2026/9578814))
- Portfolio construction: add future UK positions from different sectors to reduce reliance on advanced industrials and defence spending.
- Trading discipline: confirm that price feeds and trade execution are tied to the intended London Stock Exchange lines.
Bottom Line
The UK Portfolio is still in its build-out phase. Oxford Instruments is under pressure, but the drawdown is too new to justify a closure, and the recent order data gives the position room to prove itself. QinetiQ remains the stronger current anchor thanks to backlog visibility, improved margins, free cash flow, dividend growth and buyback support. The portfolio should hold both positions this week while prioritising diversification and quote-line verification.
Risk disclaimer: This article is for informational and editorial portfolio-review purposes only. It is not personal financial advice or a recommendation to buy or sell any security. Investing involves risk, including possible loss of principal. Always do your own research and consider your objectives, risk tolerance and liquidity needs.